Skin stem cells, essential for continual skin regeneration and repair, have now been shown to retain a remarkably persistent memory of inflammatory events. This revelation emerged from a collaborative study led by computational biologist Dana Pe’er, PhD, and stem cell biologist Elaine Fuchs, PhD. The research dissected the chromatin accessibility landscape of skin stem cells following inflammatory stimuli, demonstrating that particular regions within the DNA maintain an “open” configuration for over a year, even as cells repeatedly divide to replenish the epidermis. This epigenetic persistence suggests that stem cells are not merely passive rebuilders but are biochemically programmed to recall prior insults and respond more rapidly upon re-exposure.

The team employed advanced machine learning models trained to recognize patterns in DNA sequences associated with long-term epigenetic alterations. Their computational approach pinpointed sequence motifs that encode the heritable nature of these chromatin states, revealing that the genome intrinsically directs methylation and chromatin dynamics across successive generations of cells. Such findings underscore a paradigm in which inflammatory memory is molecularly inscribed within the genome’s regulatory architecture, poised to influence how skin tissue adapts—or maladapts—with age and repeated environmental challenges. These insights raise compelling questions about the relationship between persistent inflammation, tissue dysfunction, and age-associated diseases, marking a new frontier in dermatological biology.

In parallel, the MSK team undertook an unprecedented genomic survey of nearly 50,000 cancer patients spanning almost 450 cancer types, leveraging data from MSK-IMPACT®, their robust tumor sequencing platform. The comprehensive analysis unveiled a striking complexity in mutation behavior contingent on the cancer context. While certain mutations act as primary oncogenic drivers in their canonical tumor types, fueling early tumor initiation and present ubiquitously across malignant cells, these very same mutations display divergent roles when found in atypical cancers. They tend to emerge later in tumor evolution, are restricted to subclonal populations, and have attenuated oncogenic functions. This nuanced understanding challenges the conventional “one mutation, one action” dogma and demands refined classification frameworks in precision oncology, tailoring therapeutic decisions to the specific genetic and cellular milieu of each tumor.

Beyond elucidating driver mutation dynamics, the extensive dataset provided fresh angles on cancer genetics, highlighting the influence of fusion genes in cancers presenting at an early age as well as revealing correlations between patients’ genetic ancestry and responsiveness to immunotherapies such as T cell receptor (TCR) treatments. The transparent availability of this enormous dataset through MSK’s cBioPortal for Cancer Genomics empowers the global research community to further dissect and harness these data to optimize personalized cancer care.

In a revealing investigation into cancer cells’ innate ability to evade immune surveillance, researchers from John Maciejowski’s lab at the Sloan Kettering Institute identified the protein BAF (barrier-to-autointegration factor) as a critical mediator in masking chromosomal instability signals. Tumors often exhibit chromosomal instability characterized by improper chromosome segregation during cell division, generating micronuclei—small extranuclear DNA bodies prone to rupture, which should alert intrinsic immune defenses. BAF functions by coating the exposed micronuclear DNA upon rupture and recruiting TREX1, an exonuclease that degrades cytosolic DNA fragments, thereby attenuating the activation of the DNA sensor cGAS and preventing the elicitation of cancer-directed immune responses.

Strikingly, depletion of BAF unleashes cGAS’s access to the micronuclear DNA, triggering a potent antitumor immune response. Furthermore, simultaneous ablation of TREX1 amplifies this effect, confirming that both components collaboratively suppress innate immune detection pathways. This discovery exposes a novel immune evasion mechanism exploited by chromosomally unstable cancers and identifies BAF as a promising therapeutic target to disrupt tumor immune camouflage, potentially enhancing responses to immunotherapies.

The final revelation from MSK concerns the epigenetic underpinnings of cellular differentiation, addressing a fundamental question in developmental biology: are enhancer elements—the genomic switches that activate gene expression programs—primed before cell fate commitment? Researchers at the Sloan Kettering Institute employed cutting-edge methodologies—including CRISPR-based chromatin interrogation, single-cell transcriptomics, and chromatin accessibility assays—to interrogate human embryonic stem cells (ESCs). Their work established that enhancers associated with fully differentiated cells are pre-marked within pluripotent ESCs well before lineage specification.

These pre-established enhancers bear distinctive molecular markers, indicating a chromatin landscape configured to anticipate future gene activation. Moreover, these “pre-enhancer” regions could autonomously initiate transcriptional programs independent of external differentiation cues. This prefiguring mechanism provides a crucial framework for understanding how pluripotent cells are epigenetically equipped to embark on diverse developmental trajectories, facilitating refined strategies for cellular reprogramming and regenerative medicine.

Co-corresponding author Julian Pulecio, PhD, emphasizes that decoding these chromatin features offers novel opportunities to model gene regulatory networks, improve the precision of in vitro differentiation protocols, and elucidate how dysregulation of enhancers contributes to disease states such as cancer. Collectively, this body of research from MSK offers transformative perspectives on the interplay between genetics, epigenetics, and cell biology, heralding a new era of personalized medicine and targeted therapies.

By interrogating the layers of genomic and epigenomic regulation across health and disease, these studies illuminate the profound intricacies of cellular memory, oncogenic heterogeneity, immune interaction, and developmental priming. They underscore how interdisciplinary approaches—combining computational biology, advanced sequencing, and molecular genetics—are key to unlocking the full potential of precision oncology and regenerative science. As these discoveries continue to ripple through the biomedical community, they promise to catalyze innovative treatments and deepen our grasp of human biology at its most fundamental levels.

Subject of Research:
Skin stem cell inflammatory memory, cancer mutation heterogeneity, cancer immune evasion mechanisms, and embryonic stem cell chromatin priming.

Article Title:
Memorial Sloan Kettering Uncovers Epigenetic Memory in Skin, Mutation Complexity in Cancer, Tumor Immune Camouflage, and Developmental Enhancer Priming

News Publication Date:
2024

Web References:
Data from MSK cBioPortal for Cancer Genomics: https://www.cbioportal.org
Articles in Science, Cancer Cell, Molecular Cell, and Cell Genomics journals (specific articles referenced in the original MSK summary)

References:
Original research studies published by teams led by Dana Pe’er, Elaine Fuchs, Chaitanya Bandlamudi, Michael Berger, John Maciejowski, Yanyang Chen, Roshan Xavier Norman, and Julian Pulecio at Memorial Sloan Kettering Cancer Center and affiliates.

Image Credits:
Memorial Sloan Kettering Cancer Center

At the heart of this discovery lies a small, previously underestimated domain within one of PRC2’s core subunits, EZH2. EZH2 is the enzymatic powerhouse responsible for depositing trimethyl marks at lysine 27 of the histone H3 tail (H3K27me3), a modification that enforces transcriptional repression across the genome. Long thought structurally passive, a region termed the Stimulation Binding Domain (SBD) within EZH2 has now been illuminated as an active and indispensable regulator of PRC2’s methyltransferase function. This revelation pivots on the observation that the SBD undergoes pivotal conformational changes during the activation cycle, a finding initially highlighted through advanced cryo-electron microscopy studies that visualized these dynamic structural rearrangements.

The strategic importance of the SBD emerged definitively when researchers employed genetic deletion techniques to excise this domain from PRC2. Contrary to initial assumptions, the elimination of the SBD did not disrupt the assembly or structural integrity of the complex. This challenged the prevailing dogma that the SBD functioned merely as a scaffold for PRC2 stability. More strikingly, functional analyses revealed that without the SBD, PRC2 loses its enzymatic activity — specifically, its capacity to methylate H3K27. The absence of this methyl mark consequently results in the failure to repress target genes, effectively dismantling the epigenetic silencing machinery that normally governs developmental gene expression programs and cancer cell identity.

This nuanced understanding positions the SBD as a molecular switch controlling PRC2’s enzymatic machinery, enabling the complex to propagate repressive histone modifications genome-wide. The study’s lead author, Agata Patriotis, emphasizes that the SBD’s role transcends structural considerations; it is a functional linchpin that governs the precise “on/off” epigenetic signals crucial for diverse biological contexts, from normal embryogenesis to malignant transformation. By modulating the SBD, cells may fine-tune gene silencing states, thereby influencing key developmental trajectories and disease processes.

Most compellingly, the functional indispensability of the SBD translates directly into oncological relevance. Given that aberrant EZH2 activity and mutations are prevalent features in a host of aggressive malignancies, researchers next probed the consequences of SBD loss in cancer models. Strikingly, deletion of the SBD in lymphoma cells harboring oncogenic EZH2 mutations sharply curtailed their proliferative capacity. This abrogation of growth phenocopies the effects wrought by potent clinical inhibitors currently undergoing trials, underscoring the SBD’s potential as a highly specific drug target. The domain’s accessibility and critical role in catalytic activation render it a promising “Achilles’ heel” for therapeutic development.

The broader implications of these findings resonate with the visionary work of C. David Allis, whose pioneering research fundamentally reshaped our understanding of chromatin dynamics and histone modifications as central regulators of gene expression. The realization that enzymes like PRC2 contain embedded regulatory domains controlling their activity speaks to a universal biological principle: evolution has encoded critical functional control switches within molecular machines governing life’s fundamental processes. This discovery not only advances the conceptual framework for epigenetic regulation but also illuminates new paths for precision oncology.

Delving deeper into the biophysical mechanisms, the SBD appears to mediate allosteric communication between substrate recognition and catalytic execution within EZH2. By undergoing conformational shifts upon binding cofactors or nucleosomal substrates, the SBD likely orchestrates enzymatic activation, ensuring methyltransferase activity is tightly coupled to appropriate biological contexts. Interrupting this domain disturbs this delicate regulation, effectively rendering PRC2 epigenetically inert despite intact structural contacts among other subunits.

This mechanistic insight expands the repertoire of druggable targets beyond conventional catalytic pockets to include regulatory domains that modulate enzyme functionality via structural transitions. Targeting such allosteric sites can offer selectivity advantages and circumvent resistance mechanisms that often arise with active-site inhibitors. Furthermore, since PRC2 and its enzymatic functions are conserved across metazoans, insights gleaned here possess profound evolutionary and biomedical significance.

The researchers emphasize that cancer cells exploit the epigenetic plasticity conferred by PRC2 to maintain aberrant gene expression programs that favor unchecked proliferation and survival. Disabling the SBD disrupts this epigenetic homeostasis, inducing a transcriptomic reprogramming that limits tumor growth. This positions the SBD not only as a fundamental biological switch but also as a therapeutic vulnerability that could be leveraged in combination with existing epigenetic drugs or immunotherapies.

In summary, this pioneering study overturns longstanding assumptions about the architectural roles within PRC2 and uncovers a critical functional domain governing its gene silencing activity. By elucidating the SBD’s indispensable role in methyltransferase activation and cancer cell proliferation, the work paves the way for novel inhibitor development targeting this elusive interface. As epigenetic therapies gain traction in oncology, insights like these highlight the promise of sophisticated molecular understanding translating into transformative clinical advances.

The legacy of David Allis endures not only through the monumental advances in chromatin biology but also by inspiring continued exploration into the molecular intricacies of histone-modifying complexes. This study exemplifies the enduring quest to decode the epigenetic language underlying cellular identity and cancer, bridging fundamental science with future therapeutic innovation.

Subject of Research: Molecular mechanisms of PRC2 function and its role in cancer inhibition via the EZH2 SBD domain

Article Title: Novel regulatory domain within PRC2 subunit EZH2 controls gene silencing and cancer proliferation

Web References: https://genesdev.cshlp.org/content/early/2026/02/09/gad.353070.125

References: Published in Genes & Development

Image Credits: Allis lab/The Rockefeller University

Keywords: PRC2, EZH2, SBD domain, histone methylation, H3K27me3, epigenetics, chromatin biology, gene silencing, cancer therapy, lymphoma, embryonic development, enzyme regulation

The significance of satellite 2 repeats, situated in the pericentromeric heterochromatin regions, lies in their crucial role in maintaining chromosomal stability and ensuring proper mitotic segregation. These repetitive sequences are densely populated with CpG dinucleotides, the primary targets for DNA methylation—a chemical modification pivotal for genome integrity. Aberrant methylation at these loci can precipitate genomic instability, a hallmark of cancer progression. Therefore, understanding how therapeutic demethylating agents influence satellite DNA is essential for refining treatment paradigms.

Employing the human AML cell line U937 as a model, the researchers meticulously charted DNA methylation changes at satellite 2 repeats during DAC exposure and subsequent recovery periods. Initial findings revealed a pronounced demethylation of these satellite sequences following treatment. This observation aligns with DAC’s established mechanism where it integrates into DNA, covalently traps DNA methyltransferases (DNMTs), notably DNMT1, and leads to their depletion, culminating in passive DNA demethylation during replication.

However, the study’s revelation came with the dynamic recovery phase: after 48 hours in culture post-treatment cessation, satellite 2 DNA methylation was astonishingly restored to pre-treatment levels. This restitution suggests a robust cellular mechanism counteracting the demethylating pressure imposed by DAC. Delving into the molecular underpinnings, the team identified a significant upregulation of DNMT3B expression, a de novo DNA methyltransferase known to have a predilection for satellite 2 repeats, concomitant with the remethylation event.

Intriguingly, chromatin modifications at the DNMT3B promoter emerged as a key regulator in this process. The researchers detected increased histone H3 acetylation—a marker of chromatin relaxation and transcriptional activation—specifically at the DNMT3B promoter in DAC-treated cells. This finding suggests that decitabine not only triggers hypomethylation but can indirectly enhance the transcription of genes encoding methylating enzymes, possibly as a compensatory feedback loop to restore epigenetic homeostasis.

The data paint a nuanced picture of the cellular epigenetic response to HMAs, highlighting a transient window wherein satellite DNA is vulnerable to hypomethylation and potential destabilization. Subsequent remethylation mediated by DNMT3B appears to be a cellular safeguard mechanism, arguably limiting DAC’s genomic destabilization effects. This dynamic opens a compelling avenue for future research aimed at disrupting this remethylation reset to amplify the epigenomic and cytotoxic impact of HMAs.

Considering the clinical implications, the study posits that the transient demethylation followed by remethylation at satellite sequences could undermine full therapeutic efficacy of DAC in AML and MDS patients. Satellite DNA remethylation may attenuate the genomic instability required to maximize antitumor activity, thus representing a previously unappreciated resistance mechanism. Targeting DNMT3B or modulating histone acetylation at its promoter could potentiate DAC’s cytotoxic effects by sustaining hypomethylation-induced genomic stress in leukemic cells.

Moreover, the research subtly touches on the complex interplay between DNA methylation, chromatin remodeling, and endogenous retroelement (ERE) reactivation in the context of HMA therapy. Although reactivation of EREs and the ensuing innate antiviral response have been documented as part of DAC’s cytotoxic repertoire, the specific role and timing of satellite DNA hypomethylation within this context warrant deeper investigation. The study lays the groundwork for integrating satellite repeat methylation status into the broader epigenetic landscape modulated by HMAs.

This innovative exploration into satellite 2 methylation dynamics challenges the conventional focus on gene promoter demethylation in cancer epigenetics, redirecting attention towards repetitive elements that constitute a significant portion of the genome. It underscores the need to consider the full spectrum of epigenetic alterations induced by therapeutic agents, which might collectively dictate treatment outcomes in hematologic malignancies.

Beyond immediate clinical ramifications, the findings also prompt fundamental questions about the regulation of de novo methyltransferase genes under epigenetic stress and their contribution to genome stability recovery. The observed histone acetylation changes at the DNMT3B promoter hint at epigenetic crosstalk mechanisms that could be exploited pharmacologically to tip the balance towards sustained hypomethylation and enhanced tumor cell vulnerability.

In summary, this pioneering work reveals a biphasic epigenetic response to decitabine at pericentromeric satellite 2 repeats, characterized by rapid demethylation followed by swift remethylation driven by induced DNMT3B expression. This dynamic showcases an adaptive cellular epigenetic resilience that may constrain the full therapeutic potential of HMAs in AML. These insights steer a novel trajectory for future therapeutic strategies aimed at disrupting this remethylation rebound to potentiate leukemia eradication.

The elegant interweaving of molecular biology, chromatin biochemistry, and cancer epigenetics exemplified in this study marks a significant stride towards unraveling the complexity of epigenetic therapies. As treatment resistance and partial responses continue to challenge hematologic oncology, understanding such sophisticated regulatory loops offers hope for the development of next-generation interventions that can more decisively reprogram the cancer epigenome.

This investigation not only enhances our foundational knowledge of how DAC modulates satellite DNA but also elevates the discourse on precision epigenetic targeting—a promising frontier in the ongoing fight against malignancies characterized by epigenomic alterations. As research proceeds toward clinical translation, integrating these mechanistic insights will be vital for the design of combinatorial therapies that can circumvent epigenetic resilience and improve patient outcomes.

Subject of Research: The epigenetic effects of the hypomethylating agent decitabine on pericentromeric satellite 2 DNA methylation dynamics in acute myeloid leukemia cells.

Article Title: Decitabine-mediated DNA methylation dynamics at pericentromeric satellite 2 repeats

Article References:
Sordini, E., Ciurlia, E., Zanella, A. et al. Decitabine-mediated DNA methylation dynamics at pericentromeric satellite 2 repeats. BMC Cancer 25, 1778 (2025). https://doi.org/10.1186/s12885-025-14998-w

Image Credits: Scienmag.com

DOI: 10.1186/s12885-025-14998-w (Published 18 November 2025)

Dr. Licht’s distinguished career encompasses over two decades of pioneering research in the molecular mechanisms governing blood cancers. His work elucidating epigenetic dysregulation in leukemogenesis has opened new pathways for targeted therapies. Notably, his investigations revealed recurring mutations present in a substantial subset of relapsed B cell acute lymphoblastic leukemia (ALL) in pediatric patients and multiple myeloma cases. This discovery highlights the therapeutic potential of reversing aberrant epigenetic states as a disease-modifying strategy.

Licht’s academic trajectory began with a foundational medical education at Columbia University, followed by rigorous clinical training including a residency at Beth Israel Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute. His faculty appointments include notable tenures at Mount Sinai and Northwestern University, where he integrated clinical expertise with cutting-edge research initiatives. Most recently, at the University of Florida Health Cancer Institute, Licht’s leadership culminated in the center’s designation as a National Cancer Institute cancer center, underscoring his strategic vision and administrative acumen.

Van Andel Institute’s CEO and Chairman, David Van Andel, expressed enthusiasm about Licht’s appointment, citing his innovative approach to cancer biology and commitment to collaborative research frameworks. The institute aims to leverage Licht’s experience toward expanding interdisciplinary programs that interface epigenetics with neurodegeneration and metabolic diseases, areas increasingly recognized for their intertwined molecular underpinnings.

Beyond his scientific accomplishments, Licht’s editorial and organizational contributions have significantly shaped hematological oncology. He serves as the founding editor-in-chief of the journal Blood Neoplasia and has held editorial roles with Oncogene, Cancer Discovery, Cancer Cell, and Blood Cancer Discovery. His leadership extends to influential roles in professional societies such as the American Society of Hematology and the American Association for Cancer Research, contributing to the field’s evolving clinical and research frontiers.

The cornerstone of Licht’s laboratory research focuses on characterizing the epigenetic alterations that drive malignant transformation and progression in hematological cancers. By harnessing genomic and biochemical approaches, his team investigates the dynamic chromatin landscape governing gene expression programs critical for cancer cell survival and resistance mechanisms. This research enriches the understanding of how epigenetic therapeutics may be tailored to disrupt oncogenic circuits selectively.

Dr. Licht emphasizes the importance of translational science that bridges molecular discoveries with clinical application. His initiatives foster collaborative partnerships between academic institutions, healthcare centers, and industry stakeholders to accelerate the development of novel epigenetic inhibitors and combinational treatment regimens. Such efforts align with Van Andel Institute’s mission to translate foundational insights into tangible interventions benefitting patients worldwide.

In his forthcoming role, Licht intends to cultivate cross-disciplinary collaborations that amplify Van Andel Institute’s strengths in structural biology, cell biology, and biomedical informatics. By synergizing these domains, the institute is poised to deepen mechanistic insights and expedite biomarker discovery, thereby enhancing precision medicine strategies across a spectrum of diseases beyond hematology, including neurodegenerative disorders.

Peter A. Jones’s enduring impact as a pioneer in cancer epigenetics laid the groundwork for Van Andel Institute’s ascendancy as a global leader in biomedical innovation. His continued engagement as a faculty member ensures the institute remains tightly integrated with cutting-edge clinical trial networks, including the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team, which probes promising novel therapies in oncology.

Dr. Licht’s prolific scientific output—comprising over 240 peer-reviewed publications amassing more than 37,000 citations—reflects an impactful body of work that blends mechanistic insight with clinical relevance. His accolades, including the American Society of Hematology Basic Science Mentor Award and election as a fellow of the American Association for the Advancement of Science, affirm his role as both a visionary researcher and dedicated mentor.

As Van Andel Institute embarks on this new chapter under Licht’s stewardship, the convergence of expert leadership and a dynamic research environment promises to catalyze breakthroughs in understanding and treating complex diseases. The institute’s sustained commitment to integrating epigenetic science with innovative biomedical techniques positions it to drive transformative advances benefiting patients globally.

Situated at the nexus of a vibrant biomedical community in Grand Rapids, Van Andel Institute continues to expand its collaborative footprint across the Midwest. Licht’s strategic vision includes expanding partnerships with regional medical institutions and academic centers to foster an ecosystem that accelerates discovery, education, and clinical translation in an era of personalized medicine.

Ultimately, Jonathan D. Licht’s appointment heralds a future where Van Andel Institute’s pioneering science will increasingly unravel the epigenomic basis of cancer and other diseases, while training the next generation of biomedical scientists capable of navigating the complexities of human health and disease. His leadership signals a renewed commitment to scientific excellence, collaborative innovation, and impactful patient-centered research.

Subject of Research: Hematological malignancies, epigenetic regulation of blood cancers, cancer biology, translational medicine
Article Title: Van Andel Institute Appoints Dr. Jonathan D. Licht as New President and Chief Scientific Officer
News Publication Date: October 29, 2025
Web References: https://www.vai.org; https://joneslab.vai.org; https://www.vai.org/research/research-departments/epigenetics/
Image Credits: Courtesy of Van Andel Institute
Keywords: Health and medicine, Epigenetic regulation, Cancer